Astellas is committed to ful lling its social responsibilities in the course of conducting business activities, aiming to contribute to improving the health of people around the world. We respect human rights in every stage of our value chain, from research and development to the provision of information regarding our products. We also strive to ensure compliance with the Pharmaceutical and Medical Device Act and other relevant laws and regulations.

Responsible Business Activities

 

Research

Ethical Considerations in Research on Human Subjects and Specimens Derived from Humans

Astellas conducts research on human subjects, and obtains and conducts research on specimens derived from humans,after appropriately obtaining the consent of the subjects in accordance with the Declaration of Helsinki* as well asthe laws, regulations and guidelines of relevant countries.
In Japan, Astellas provides training for researchers in areas such as bioethics, genomic research and related clinical research based on a strong commitment to respecting the human rights of research subjects and protecting the privacy and confidentiality of their personal information.
The Astellas Research Ethics Committee has been established with outside members participating in the committee to determine the ethical acceptability and scientific propriety of research plans in a fair and impartial manner.

* Declaration of Helsinki: A statement of ethical principles for medical research involving human subjects, addressed to physicians and others who are involved in medical research on human subjects.

Ethical Considerations in Stem Cell Research and Development

Astellas believes that there is a possibility of supplying new stem cell-based treatment methods to address diseases that previously had no known treatment methods. To achieve this, Astellas is advancing research and development activities focused on using stem cells in therapy.

Astellas also recognizes that research into human stem cells could give rise to concerns that warrant close examination. In particular, Astellas is fully aware of the necessity to pay full attention to the social and bioethical issues associated with research using human embryonic stem cells (ES cells).

Based on these principles and awareness, Astellas has established its “Policy on Human Stem Cell Research and Development*,” which sets forth the basic matters it must comply with in the course of conducting human stem cell research and development. Specifically, in all of its research and development activities involving human stem cells, Astellas will comply with the relevant laws, ordinances and regulations of the countries and regions where it undertakes these research and development activities. Moreover, Astellas will set up a committee comprising internal and external experts, from which it will obtain oversight and advice on the ethical aspects and the scientific legitimacy and merit of these research and development activities. All the proposals on research and development programs involving human stem cells will be reviewed and approved by the committee to ensure that these research and development activities are implemented ethically and in line with a legitimate scientific purpose. Furthermore, when establishing and using human ES cells, Astellas will take steps to satisfy the ethical standards established by the world’s major scientific authorities, including the guidelines laid out by the National Academy of Sciences of the United States of America.

* For details, please visit the following website:https://www.astellas.com/en/privacy-policy

Ethical Considerations in Animal Testing

Astellas conducts animal testing based on its Policy on Animal Care and Use. We have established the Corporate Institutional Animal Care and Use Committee with outside members participating in the committee, to determine whether to conduct animal testing based on the 4R Principles*1. All of Astellas’ animal testing facilities have acquired accreditation from AAALAC international*2.

*1 4R Principles: Developing non-animal testing alternatives and replacing animals of phylogenetically lower species (Replacement); reducing the number of animals involved to the minimum necessary to achieve the scientific purpose(Reduction); avoiding the infliction of distress on animals wherever possible (Refinement); and scientifically and ethically justifying animal use in light of their significance, necessity, predictability and other criteria (Responsibility).
*2 AAALAC International: The Association for Assessment and Accreditation of Laboratory Animal Care International. An international organization that promotes the humane treatment of animals through voluntary accreditation and assessment programs. Studies are undertaken from both scientific and ethical standpoints to verify the quality of animal control and use programs.

Biotechnology and Biohazard Control

Astellas handles genetically modified organisms and performs experiments using materials containing pathogens in compliance with the World Health Organization Laboratory Biosafety Manual*1, the U.S. Centers for Disease Control (CDC) Biosafety Manual*2 and the U.S. National Institutes of Health Guidelines*3, as well as the laws of individual countries.

*1 Laboratory Biosafety Manual 3rd Edition
*2 Biosafety in Microbiological and Biomedical Laboratories 5th Edition
*3 NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules

Use of Genetic Resources

Astellas has published its Position on Genetic Resources, and is committed to full compliance with the relevant laws and regulations of countries supplying genetic resources, and to the fair distribution of profits derived from the use of such resources according to the conditions mutually agreed upon with each country. This commitment is based on the concept of genetic resource utilization and the associated distribution of profits set out in the Nagoya Protocol*1 adopted by the Conference of the Parties to the Convention on Biological Diversity*2. The impacts of the use of new genetic modification technologies on the environment, biodiversity, and human health are not fully known. Therefore, Astellas will proceed cautiously when using these technologies while remaining mindful of the need to preserve biodiversity and consider ethical issues.

*1 Nagoya Protocol: Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization
*2 The Convention on Biological Diversity: International convention on the sustainable use and conservation of biological diversity

Treatment of Intellectual Property

Appropriate protection of intellectual property is critical to addressing unmet medical needs and maintaining a competitive advantage. With this in mind, Astellas has established a Policy on Intellectual Property. In view of the importance of improving people’s access to health, Astellas participates in the Patent Information Initiative for Medicines (Pat-INFORMED) implemented by the World International Patent Organization (WIPO) to ensure easy access to Astellas’ patent information on medicines by health agencies tasked with the procurement of medicines in various countries.
Moreover, we are committed to not filing or enforcing patents in countries facing significant economic challenges. These select countries are decided by referring to those designated as Least Developed Countries (LDCs) defined by the United Nations or Low Income Countries (LICs) defined by the World Bank.

 

Close

Clinical Development

Respect for Human Rights, Protection of the Privacy and Confidentiality of the Personal Information of Clinical Trial Subjects, and Assurance of Reliability in Clinical Trials

Astellas conducts clinical trials to assess the efficacy and safety of new drug candidates in patients under the Declaration of Helsinki, Good Clinical Practice (GCP) and all relevant laws and regulations with full consideration to protecting human rights and the privacy and confidentiality of clinical trial subjects’ personal information. Clinical study protocols developed by Astellas are evaluated and approved for ethical acceptability and scientific validity by internal and external evaluation committees.
In conducting clinical trials, Astellas confirms that clinical trial subjects have provided informed consent, having received a full explanation of the purpose and methods of the trial, its expected benefits and disadvantages, matters related to compensation for health impairment and other details. Moreover, we implement education and training for any employees or staff members involved in clinical trials, and monitor medical institutions that perform clinical trials to ensure full GCP compliance.
In addition, we manage trial data appropriately to protect the privacy and confidentiality of the personal information of clinical trial subjects. Periodic assessments are also made to check that any outsourced clinical trials are conducted in accordance with the same standards.

Disclosure of Information on Clinical Trials and Trial Results

Astellas is committed to increasing transparency and providing disclosure of clinical trial data. Maximizing the value of clinical trial data, and putting it to good use in driving scientific advancement and increasing innovation, requires that the clinical trial data be appropriately accessible to the research community and others who might utilize it. The Policy on Disclosure of Clinical Trial Data has been published on the Company website to present Astellas’ position on this matter.
Specifically, Astellas provides patient-level data that have been anonymized in accordance with applicable laws and regulations through an external website*1 to those scientists and healthcare professionals requesting it. Doctors and the public can confirm summaries of clinical trial findings via the website for clinical trial data disclosure.  This website also gives patients access to plain language summaries of study results prepared for non-experts*2.

*1 Patient-level data are provided through the following website: http://www.clinicalstudydatarequest.com
*2 Results of the clinical trials are provided through the following website: https://www.astellasclinicalstudyresults.com/Welcome.aspx

 

Expanded Access to Investigational Medicines

Astellas has set forth its approach to supplying investigational medicines to patients for purposes other than clinical studies in its Position on Expanded Access to Investigational Medicines*.

Astellas recognizes that patients with serious or life-threatening diseases may have exhausted all of their available treatment options, may not qualify for a clinical trial and may seek access to investigational medicines. In these cases, in response to a request for investigational medicines from a primary physician, Astellas fairly, impartially and rapidly evaluates whether or not the patient meets the required conditions and commits to establishing an expanded access plan as appropriate. The expanded access program will target countries where the clinical development of an investigational medicine is progressing and the drug is scheduled to obtain approval. Moreover, this procedure will be implemented in accordance with the regulations of the country where expanded access is requested.

* For details, please visit the following website:
https://www.astellas.com/en/about/policies-and-position-statements?param=expend-tit-medicines

Patient Centricity in Clinical Drug Development

Real-world considerations in clinical trials are increasingly important in ensuring that our studies address current medical practices and patient needs. 
Patient centricity is now a focus for regulatory authorities and the pharmaceutical industry. The patient-centric approach is being discussed at all points in the drug development value chain, from discovery through to commercialization.
We are pursuing patient centricity in clinical development. To do so, we are trying to incorporate insights from real-world data into the planning of clinical trials by understanding how healthcare is provided to patients. Efforts are being made to include patient input in how to optimally design clinical trials, recruit participants, and identify relevant endpoints that patients care most about. 
For example, we use patient-reported outcomes (PROs) such as questionnaires and patient diaries to monitor and assess patients’ health conditions. In addition, we use real-world data for estimation of target populations based on the morbidity rate and ineligible cases in screening, and feasibility of studies in clinical trial facilities. As a pilot project, we established a patient-friendly website for an investigational drug to support patient/caregiver-focused recruitment and health literacy recommendations. Especially in the muscle disease field, we are working with patient organizations. Working closely with those organizations, we are striving to reflect valuable insights from patients and caregivers in clinical trial designs. Through these activities, we try to make it easier for patients to participate in clinical trials, as we work to obtain trial results with greater clinical significance.

Close

 

Quality and Reliability Assurance

Anti-counterfeiting Activities

The distribution of counterfeit medicines in legitimate supply chains not only leads to the loss of opportunities for patients to receive medical treatment but could also have adverse health consequences. This has become a serious problem worldwide.
 Astellas operates the Anti-Counterfeit Committee, led by the supply chain management and quality assurance divisions, and has a product security division. These parts of Astellas conduct monitoring and surveys, and implement countermeasures targeting not only counterfeit medicines, but also diversion, smuggling, theft and related activities. When selling products, Astellas systematically introduces effective anti-counterfeit technologies, including product serialization of secondary product packaging as stipulated by regulations, based on pharmaceutical laws and regulations and risks in each market where products are sold, as well as product characteristics. In addition, Astellas carries out educational activities to prevent the spread of counterfeit medicines in collaboration with members of the pharmaceutical industry and organizations such as the World Health Organization (WHO), the PSI* and the Transported Asset Protection Association. We also proactively endeavor to support and cooperate with national governments and judicial authorities to crack down on counterfeit medicines. Astellas publishes its Position on Counterfeit Medicines on its website.

*PSI: Pharmaceutical Security Institute

Product Recalls

Astellas has a recall system in place that is activated when the safety, efficacy or quality of a product is brought into question. The system ensures relevant information is promptly passed on to medical institutions and other affected parties, and that a recall of the product in question is instigated. Astellas voluntarily initiated three product recalls in fiscal 2017. As of March 2018, no reports of any related health impairments had been received.

Anti-doping Measures

Doping is an issue closely related to abuse and misuse of medicines in sports. It is a serious priority for the pharmaceutical industry given that it is not only associated with a risk of inducing serious side effects, but it can also become a breeding ground for the unauthorized distribution and counterfeiting of medicines. Astellas is working to identify the compounds under development that have the potential to be used in doping and to prevent the misuse of those compounds.

In October 2016, Astellas made a global agreement with the World Anti-Doping Agency (WADA)T to partner on the prevention of misuse and abuse of medicines for doping in sports owhich aims to contribute to the eradication of doping and improvement of public health.

Doping in sports relies primarily on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as well-known or easily detected. To support WADA in its efforts to address this issue, Astellas identifies compounds solely developed by Astellas or its affiliates with the potential for sport-related doping abuse and cooperates in sharing relevant information to aid WADA in the organization’s development of detection methods for these compounds. Additionally, Astellas cooperates with WADA to minimize the risk of misuse of compounds with doping potential during clinical trials to avoid opportunities for abuse.

Quality Assurance Policy

Astellas has set forth global policies concerning quality assurance in the Astellas Quality Assurance Manual. Based on this manual, we prepare guidelines and standard operating procedures concerning quality assurance systems and operational management and procedures for a variety of quality assurance related activities at the global, regional and national levels. Education and training programs are implemented to promote understanding and awareness of these matters.

These documents are revised periodically and as necessary. We respond swiftly to developments in the external environment, such as regulatory changes and amendments.

Improving the Pharmacovigilance (PV) System

Astellas is continuously improving its PV system by strengthening collaboration between the internal PV function and other relevant departments, affiliates and licensing partners. This is to support the provision of trustworthy product information and proper product use, along with regulatory compliance. 
Astellas regularly provides product safety awareness training not only to staff closely involved with the PV function but also to all employees and contractors including affiliate staff, to maintain and strengthen swift and appropriate collection of product safety information. For external service providers outsourced by departments other than the PV division, Astellas updates their contracts to add requirements for safety management information collection as necessary. Through these measures, Astellas is building a system for collecting information over a wide scope.
In addition, Astellas is exploring utilizing real-world data such as large healthcare databases for safety signal detection of Astellas products to help minimize risk by enhancing collaboration between PV and other functions. Furthermore, Astellas PV has started exploring and assessing automation technologies and artificial intelligence technologies that can be used for safety data monitoring, processing and reporting, and earlier identification and analysis of safety signals. We plan to use these technologies to strengthen our safety data management systems.

Strengthening of Quality Assurance Systems at Affiliates

Astellas has constructed a robust global quality assurance system to ensure the supply of pharmaceuticals of uniformly high quality to patients worldwide.
The past quality assurance system comprised the four main regions of Japan, the Americas, EMEA and Asia & Oceania. We are trying to incorporate quality assurance activities taken by each affiliate into this global quality assurance structure. Through this change, we are developing quality management systems consistent with our quality assurance policy on a global, Company-wide basis. This will reinforce our sales affiliates globally receive proper support in improving quality and training personnel.

Close

Technology Development & Manufacturing

Stable Supply and Quality Control

Astellas places highest priority on ensuring stable manufacture and supply of safe and effective pharmaceuticals to patients. To ensure this, we have established our own Good Manufacturing Practice (GMP)-compliant quality standards as the basis for consistently achieving high levels of quality control. We apply these standards to manufacturing facilities and equipment, and to all stages from raw material procurement and storage to production and shipment.

Measures to Prevent Medical Malpractice and to Improve the Distinguishability of Pharmaceuticals

Astellas strives to supply products from the users’ perspective to ensure that healthcare professionals and patients do not mistake one pharmaceutical for another. We are working to prevent medical malpractice in this respect, through measures including printing product names directly on capsules and tablets, as well as printing product names and dosage on packaging sheets (blister sheets) so that the product name and dosage can be easily identified even after the blister sheet is split apart.

To prevent misreading of labeling on blister sheets, Astellas also endeavors to make products easier to identify visually by adopting easily discernible colors and font types for the blister sheets of certain products.

Introducing Universal Design into Product Packaging

img of Universal design packaging of Bonoteo 50mg tablets
Universal design packaging of Bonoteo 50mg tablets

We have introduced universal design to certain product packaging. For example, the universal design packaging of Bonoteo 50 mg tablets, which is administered once every 4 weeks, features packaging with good openability. To prevent patients from forgetting to take the drug, there is an area provided on the packaging to write in the day when the drug should be taken. A small label to be used as a calendar is also attached. In addition, the packaging uses a universal design font type for easy reading.

Relationship with Local Communities

To promote sustainable pharmaceutical manufacturing, Astellas arranges opportunities for dialogue with local residents and communities near its manufacturing sites. By proactively disclosing its initiatives, Astellas is working to build good relationships with them.
At the Kerry Plant in Ireland, Astellas is launching annual events with the local community to protect the environment, ensure health and safety, and save energy. Each year, the event themes revolve around environmental protection, health and safety, and energy conservation, and local children draw pictures with the themes. These are made into a calendar which is sold locally, with all proceeds donated to the Irish Kidney Association. Every year, over 1,000 entries are received from 12 schools, and the event is now being developed into a regular community event. In 2017, we received the SEAI* Award as one of Ireland’s leading companies.

SEAI: Sustainable Energy Authority of Ireland is an Irish government-affiliated organization supporting the reduction of CO2 emissions.

Close

Provision of Product Information

Ensuring Proper Use

Astellas’ Medical Representatives (MRs) provide information on appropriate usage based on on-label information to healthcare professionals to ensure that Astellas pharmaceutical products are used safely and effectively. In promotion of Astellas products, MRs observe high ethical standards and strictly observe the Astellas Group Code of Conduct, local codes of conduct, and the relevant laws and regulations in each country. 
Medical Science Liaisons (MSLs) engage with healthcare professionals to exchange scientifically based information to advance their understanding and the safe and effective use of our products in patient care. MSLs observe high ethical standards and provide reliable, clear, fair, balanced and unbiased medical and scientific information. MSLs refrain from promotion of products, and observe high ethical standards, making compliance their top priority.

Responding to Inquiries

Astellas has a responsibility to provide truthful, balanced and unbiased medical information in response to inquiries regarding our products. By fulfilling this responsibility, Astellas supports the safe and effective use of our products.
 In countries throughout the globe, we have Medical Information Call Centers that respond to a variety of inquiries. In our larger call centers, we have systems that allow for 24-hour responses to urgent inquiries, even on business holidays. In fiscal 2017, we responded to approximately 160,000 inquiries.
 Astellas makes continuous efforts to improve its medical information services, with the aim of providing accurate, appropriate and consistent information. As part of these efforts, a global medical information system is used where medical responses from Group companies around the world are documented. This enables the responses to be communicated to our customers in a simple, swift and accurate manner. At the same time, we can analyze feedback from patients and medical professionals and inform the life cycle management of our products.

Close

Procurement

Promoting CSR Procurement

Astellas considers it important to fulfill its social responsibilities across the entire supply chain, including suppliers. To achieve this goal, Astellas has formulated the Astellas Business Partner Code of Conduct, which requires business partners to do their business in accordance with CSR measures. We also conduct global questionnaire-based surveys based on the code, along with requesting our business partners to sign the Acknowledgement of Astellas Business Partner Code of Conduct. As of March 31, 2018, we had obtained survey responses from approximately 900 companies, covering suppliers of direct materials, as well as major suppliers of indirect materials and major facility and equipment suppliers. In fiscal 2017, we widened the scope of the survey to include pharmaceutical wholesalers, licensees, distributors and banks. Furthermore, we conduct on-site audits of suppliers in countries that pose a high CSR procurement risk.

Close